Fennec Pharmaceuticals (TSE:FRX) has released an update.
Fennec Pharmaceuticals has reported a successful fiscal year with PEDMARK sales reaching $21.3 million, buoyed by a robust fourth quarter and an exclusive licensing deal with Norgine for PEDMARQSI in Europe, Australia, and New Zealand that could bring in an additional $230 million. The company’s cash position is strong, with a pro forma cash balance over $55 million, and its financial outlook is positive with enough funds to maintain operations for the next year.
For further insights into TSE:FRX stock, check out TipRanks’ Stock Analysis page.
